Patient handout

Atrial flutter in cardiac amyloidosis (ATTR-CM and AL)

PRODUCTION

1. Your condition

This handout is for atrial flutter in cardiac amyloidosis (attr-cm and al). Your care team identified this based on: atrial flutter on ecg/telemetry + lv wall thickness ≥12 mm + no long-standing htn — amyloidosis screen.

Other reasons your team may use this plan: afl with low-voltage qrs + thick lv walls (voltage-mass mismatch — amyloid signature); elderly male with bilateral carpal tunnel release history + new afl — attrwt clue; apical sparing pattern on speckle-tracking strain echo + afl (cherry-on-top amyloid signature).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
metoprolol_succinate	LOW DOSE START: 12.5 mg PO daily, titrate q1–2 wk to max tolerated (often 25–50 mg daily ceiling in amyloid); reassess SBP + orthostasis + functional status before each titration	PO	daily	AVN slowing for AFL but amyloid patients have narrow tolerance; ESC 2023 (PMID 37596926) acknowledges BB poorly tolerated; many require dose ceilings or discontinuation; Kittleson 2023 (PMID 37290437) recommends individualized cautious approach
diltiazem	CAUTIOUS LOW-DOSE: diltiazem CD 120 mg PO daily start (NOT 240–360 mg); avoid IV unless absolutely necessary; AVOID if EF <40 or SBP <100	PO	daily	AVN slowing alternative; CAUTIOUS — non-DHP CCBs also bind amyloid (less than digoxin) and worsen restrictive failure; ESC 2023 (PMID 37596926) cautions on use; AVOID in HFrEF or significant orthostasis
apixaban	5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5)	PO	BID	ARISTOTLE (Granger NEJM 2011 PMID 21870978); preferred DOAC in amyloid given lowest bleed risk profile; Kittleson 2023 (PMID 37290437) — AC even at low CHA2DS2-VASc due to atrial myopathy thrombus risk
rivaroxaban	20 mg with food (15 mg if CrCl 15–50)	PO	once daily	ROCKET-AF (Patel NEJM 2011 PMID 21830957); higher bleed risk than apixaban — second choice in amyloid
edoxaban	60 mg daily (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor); avoid CrCl >95	PO	once daily	ENGAGE-AF-TIMI-48 — alternative DOAC
warfarin	5 mg daily; INR target 2–3	PO	daily	Warfarin in AL with factor X deficiency may be safer in select cases (DOAC anti-Xa effect compounds bleeding risk); coordinate with hematology
tafamidis	61 mg PO daily (free acid; equivalent to tafamidis meglumine 80 mg); lifelong	PO	daily lifelong	ATTR-ACT (Maurer NEJM 2018 PMID 30145930) — 30% all-cause mortality reduction over 30 mo; greatest benefit NYHA I–II; may slow AFL substrate progression by reducing atrial amyloid deposition
patisiran	0.3 mg/kg IV every 3 weeks (premedicate with dex/H1/H2/acetaminophen)	IV	every 3 weeks	APOLLO (Adams NEJM 2018 PMID 30144829) — siRNA reduces hepatic TTR production
vutrisiran	25 mg SC every 3 months	SC	every 3 months	HELIOS-A (Adams Lancet Neurol 2023 PMID 35262029) — SC dosing convenience
daratumumab	1800 mg SC weekly × 8, then biweekly × 16, then monthly (with bortezomib + cyclophosphamide + dex — D-VCd regimen)	SC	per ANDROMEDA schedule	ANDROMEDA (Kastritis NEJM 2021 PMID 34077641) — daratumumab + CyBorD improved hematologic CR + organ response in AL; AFL component managed simultaneously
amiodarone	150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance	IV/PO	load + daily	Most efficacious AAD in structural heart disease; safer than class IC in amyloid; pulm/thyroid/hepatic toxicity monitoring required; ACC/AHA 2024 (PMID 38753446)

Plan: Atrial flutter in cardiac amyloidosis — amyloid-type phenotype-specific (AL vs ATTRwt vs ATTRv) rate control + AC + disease-modifying pathway with critical drug-class avoidance — ESC 2023 amyloidosis (PMID 37596926) + ACC/AHA 2024 AF (PMID 38753446) + Kittleson 2023 (PMID 37290437) + ATTR-ACT (PMID 30145930)

3. When to call your provider

Contact your care team if any of the following happen:

Recurrent AFL despite ablation → repeat EP — lower expected re-success in amyloid; consider rate control + AC continuation as pragmatic strategy
New AF after CTI ablation → AF management (cardio.afib.core.v1) — common in amyloid (atrial myopathy)
Major bleed on AC → reverse + reassess long-term strategy
Tafamidis ineffective (progression) → add patisiran or vutrisiran
New advanced AV block → PPM evaluation
AL FLC rising or new organ involvement → hematology re-induction
ADHF in amyloid → cardio.acute-hf.amyloidosis.v1 routing

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

Patient with cardiac amyloidosis presenting with new bradyarrhythmia, AV block, GI symptoms, visual disturbance, or altered mental status while on digoxin (often initiated outside facility for AFL rate control without amyloid recognition) — life-threatening iatrogenic emergency(life-threatening)
BB-induced symptomatic bradycardia, AV block, or worsening orthostasis in amyloid AFL patient (autonomic dysfunction + amyloid AV node sensitivity)
TEE shows LAA thrombus pre-planned cardioversion in amyloid AFL — common finding (25–30% incidence vs 5–10% in non-amyloid AFL)
AL amyloidosis (positive monoclonal screen + biopsy or PYP-negative + cardiac involvement) with rising FLC + cardiac stage III–IV (natural marker of fluid overload (NT-proBNP) >8500 + troponin elevated) presenting with AFL — combined arrhythmic + oncologic emergency(life-threatening)
SBP <90 + lactate >2 + amyloid AFL — restrictive low-output state; usually preload depletion (over-diuresis), AVN-blocker excess, or amyloid CS(life-threatening)

5. Follow-up

Amyloidosis center referral; cardiology + EP for ablation candidacy assessment (lower success expected); hematology for AL; genetic counseling for ATTRv; lifelong DOAC; tafamidis lifelong for ATTR; periodic echo + natural marker of fluid overload (NT-proBNP) for disease progression

6. Sources

Guideline: 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2023 cardiac amyloidosis position statement (PMID 37596926) + Kittleson ACC/AHA 2023 cardiac amyloidosis expert decision pathway (PMID 37290437)